Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.

NCT00056524 is registered in ClinicalTrials.gov with Avanir Pharmaceuticals as lead sponsor.

NCT NCT00056524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.
Lead sponsor
Avanir Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2003
Completion date
June 30, 2007
Enrollment
600 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, parkinson's disease, stroke, traumatic brain injury